EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY-NC 4.0

Comparative Safety Analysis of Targeted Synthetic and Biologic Disease‐Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis: A Nationwide Cohort Study in Japan

Shiori Nishimura iD, Toshitaka Hirano iD, Soko Setoguchi, Hiroki Matsui, Yoshinori Takeuchi, Yasushi Inoue, Yoshiya Tanaka iD, Kunihiro Yamaoka iD, Yoichi Ii iD, Shintaro Hiro, Masato Hoshi iD, Naonobu Sugiyama und 2 weitere

International Journal of Rheumatic Diseases · 2026

DOI: 10.1111/1756-185x.70838 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Rheumatic Diseases, 2026. Verfasst von Shiori Nishimura und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Healthcare Quality Assessment, The University of Tokyo Graduate School of Medicine, Bunkyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Biological Products. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To compare risks of malignancy, opportunistic infections, and venous thromboembolism between the targeted synthetic disease‐modifying antirheumatic drugs (tsDMARDs) and biologic DMARDs (bDMARDs) at the 2nd and 3rd lines of therapy (LOT).

Methods

We conducted a cohort study using the National Database of Health Insurance Claims (2013–2021). Patients with rheumatoid arthritis (RA) initiating tsDMARDs or bDMARDs after conventional synthetic DMARDs (csDMARDs) were identified at the 2nd LOT or 3rd LOT. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox models weighted by inverse probability of treatment weighting.

Results

Among 498 813 csDMARD initiators, 66 638 and 4177 initiated bDMARDs and tsDMARDs at 2nd LOT; 14 085 and 1757 initiated bDMARDs and tsDMARDs at 3rd LOT. For malignancy, HRs (95% CIs) for tsDMARDs versus bDMARDs were 0.92 (0.60–1.43) at 2nd LOT and 0.94 (0.53–1.65) at 3rd LOT. HRs (95% CIs) for pneumocystis pneumonia (PCP) and deep vein thrombosis (DVT) were as follows: PCP, 0.98 (0.75–1.29) at 2nd LOT and 1.12 (0.81–1.54) at 3rd LOT; DVT, 1.13 (0.64–1.99) at 2nd LOT and 0.96 (0.52–1.78) at 3rd LOT. In contrast, herpes zoster (HZ) risk was consistently higher with tsDMARDs (2nd LOT: HR, 2.61 [95% CI, 2.24–3.05]; 3rd LOT: HR, 2.90 [95% CI, 2.38–3.53]).

Conclusions

In the nationwide Japanese cohort, tsDMARDs did not show increased malignancy risk compared to bDMARDs, and PCP risk had no clear difference at 2nd and 3rd LOTs, whereas the risk of HZ was higher with tsDMARDs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAntirheumatic AgentsBiological ProductsHumansJapanFemaleMaleMiddle AgedAgedOpportunistic InfectionsVenous ThromboembolismNeoplasmsRisk FactorsRisk AssessmentAdultCohort Studies

Stichwörter der Autor:innen

Janus kinase inhibitorbiologic disease‐modifying antirheumatic druginfectionmalignancytargeted synthetic disease‐modifying antirheumatic drugvenous thromboembolism

Substanzen

Antirheumatic AgentsBiological Products

Autor:innen und Institutionen

  • Department of Healthcare Quality Assessment, The University of Tokyo Graduate School of Medicine, Bunkyo, Tokyo, Japan.
  • Department of Health Data Science, Graduate School of Data Science, Yokohama City University, Yokohama, Kanagawa, Japan.
  • Pfizer Japan Inc., Shibuya, Tokyo, Japan.
  • Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
  • Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Bunkyo, Tokyo, Japan.
  • Department of Data Science, School of Data Science, Yokohama City University, Yokohama, Kanagawa, Japan.

ORCID-Profile: Shiori Nishimura, Toshitaka Hirano, Yoshiya Tanaka, Kunihiro Yamaoka, Yoichi Ii, Masato Hoshi, Yutaka Matsuyama, Hiraku Kumamaru

Förderung

  • Pfizer

Zitieren

APA

Nishimura, S., Hirano, T., Setoguchi, S., Matsui, H., Takeuchi, Y., Inoue, Y., Tanaka, Y., Yamaoka, K., Ii, Y., Hiro, S., Hoshi, M., Sugiyama, N., Matsuyama, Y., & Kumamaru, H. (2026). Comparative Safety Analysis of Targeted Synthetic and Biologic Disease‐Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis: A Nationwide Cohort Study in Japan. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70838

Vancouver

Nishimura S, Hirano T, Setoguchi S, Matsui H, Takeuchi Y, Inoue Y, et al. Comparative Safety Analysis of Targeted Synthetic and Biologic Disease‐Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis: A Nationwide Cohort Study in Japan. International Journal of Rheumatic Diseases. 2026. doi:10.1111/1756-185x.70838

BibTeX
@article{Nishimura2026,
  author = {Nishimura, Shiori and Hirano, Toshitaka and Setoguchi, Soko and Matsui, Hiroki and Takeuchi, Yoshinori and Inoue, Yasushi and Tanaka, Yoshiya and Yamaoka, Kunihiro and Ii, Yoichi and Hiro, Shintaro and Hoshi, Masato and Sugiyama, Naonobu and Matsuyama, Yutaka and Kumamaru, Hiraku},
  title = {Comparative Safety Analysis of Targeted Synthetic and Biologic Disease‐Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis: A Nationwide Cohort Study in Japan},
  journal = {International Journal of Rheumatic Diseases},
  year = {2026},
  doi = {10.1111/1756-185x.70838}
}
Kostenlos starten →